United Therapeutics Corporation (NASDAQ:UTHR) Receives $646.00 Consensus Target Price from Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has been given an average rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $646.00.

Several research firms recently issued reports on UTHR. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Finally, Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th.

Insider Activity

In related news, Director Nilda Mesa sold 228 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $505.87, for a total transaction of $115,338.36. Following the transaction, the director directly owned 5,580 shares of the company’s stock, valued at $2,822,754.60. This trade represents a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $501.39, for a total value of $4,763,205.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $162,672,475.77. The trade was a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 364,303 shares of company stock worth $190,312,234 over the last quarter. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Toth Financial Advisory Corp increased its position in United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after buying an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics during the second quarter valued at about $30,000. Entrust Financial LLC purchased a new stake in United Therapeutics during the fourth quarter valued at about $31,000. Caitlin John LLC bought a new position in United Therapeutics during the second quarter worth about $37,000. Finally, International Assets Investment Management LLC boosted its holdings in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Down 0.5%

Shares of NASDAQ UTHR opened at $494.63 on Wednesday. The firm has a market cap of $21.21 billion, a PE ratio of 17.70, a P/E/G ratio of 2.49 and a beta of 0.56. The company’s fifty day simple moving average is $515.48 and its 200 day simple moving average is $540.32. United Therapeutics has a 12-month low of $408.75 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the firm posted $6.41 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics will post 26.21 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.